PURPOSE: Complement regulators control the activated complement system. Defects in this homeostasis can result in tissue damage and autoimmune diseases with a heterogeneity in clinical presentation. Complement factor I (FI), a serine protease, is an important regulator of alternative pathway activation. We report a diagnostic work-up of a patient with relapsing inflammatory mediated meningo-encephalitis. Our work-up revealed a rare genetic factor I (FI) deficiency. So far, all cases of reported complete factor I deficiency have absent serum levels of FI. We present here a unique case of a complete factor I deficiency based on a functional FI defect. METHODS: Complement assays and measurement of FI activity were performed in the patient, her family, factor H-deficient patients, a patient with C3-nephritic factor and 11 healthy controls. Genetic sequencing of the FI coding regions in the patient and her parents was performed. RESULTS: The patient had absent alternative pathway activity with low levels of C3 and normal serum level of FI. The patient's plasma FI did not degrade C3b, with normalisation of C3b degradation after adding purified FI. Mutation analysis of the complement factor I gene revealed two heterozygous mutations (I322T and D506V). CONCLUSION: To our knowledge, this paper describes a complete FI deficiency caused by a defect of FI activity for the first time. Normal FI concentration does not exclude a complete FI defect, additional functional analysis of FI is required in any patient with a defect of complement activation. Recurrent aseptic meningo-encephalitis is a rare clinical presentation of complete FI deficiency.
PURPOSE: Complement regulators control the activated complement system. Defects in this homeostasis can result in tissue damage and autoimmune diseases with a heterogeneity in clinical presentation. Complement factor I (FI), a serine protease, is an important regulator of alternative pathway activation. We report a diagnostic work-up of a patient with relapsing inflammatory mediated meningo-encephalitis. Our work-up revealed a rare genetic factor I (FI) deficiency. So far, all cases of reported complete factor I deficiency have absent serum levels of FI. We present here a unique case of a complete factor I deficiency based on a functional FI defect. METHODS: Complement assays and measurement of FI activity were performed in the patient, her family, factor H-deficientpatients, a patient with C3-nephritic factor and 11 healthy controls. Genetic sequencing of the FI coding regions in the patient and her parents was performed. RESULTS: The patient had absent alternative pathway activity with low levels of C3 and normal serum level of FI. The patient's plasma FI did not degrade C3b, with normalisation of C3b degradation after adding purified FI. Mutation analysis of the complement factor I gene revealed two heterozygous mutations (I322T and D506V). CONCLUSION: To our knowledge, this paper describes a complete FI deficiency caused by a defect of FI activity for the first time. Normal FI concentration does not exclude a complete FI defect, additional functional analysis of FI is required in any patient with a defect of complement activation. Recurrent aseptic meningo-encephalitis is a rare clinical presentation of complete FI deficiency.
Authors: Izabela M Nita; Ferah Genel; Sara C Nilsson; Joanne Smart; Lennart Truedsson; Sharon Choo; Anna M Blom Journal: Mol Immunol Date: 2011-02-12 Impact factor: 4.407
Authors: Lori Broderick; Chhavi Gandhi; James L Mueller; Christopher D Putnam; Katayoon Shayan; Patricia C Giclas; Karin S Peterson; Seema S Aceves; Robert M Sheets; Bradley M Peterson; Robert O Newbury; Hal M Hoffman; John F Bastian Journal: J Clin Immunol Date: 2012-08-29 Impact factor: 8.317
Authors: David Kavanagh; Anna Richards; Marina Noris; Richard Hauhart; M Kathryn Liszewski; Diana Karpman; Judith A Goodship; Veronique Fremeaux-Bacchi; Giuseppe Remuzzi; Timothy H J Goodship; John P Atkinson Journal: Mol Immunol Date: 2007-06-26 Impact factor: 4.407
Authors: Clara Franco-Jarava; Elena Álvarez de la Campa; Xavier Solanich; Francisco Morandeira-Rego; Virgínia Mas-Bosch; Marina García-Prat; Xavier de la Cruz; Andrea Martín-Nalda; Pere Soler-Palacín; Manuel Hernández-González; Roger Colobran Journal: J Clin Immunol Date: 2017-09-23 Impact factor: 8.317
Authors: Yuzhou Zhang; Renee X Goodfellow; Nicolo Ghiringhelli Borsa; Hannah C Dunlop; Stephen A Presti; Nicole C Meyer; Dingwu Shao; Sarah M Roberts; Michael B Jones; Gabriella R Pitcher; Amanda O Taylor; Carla M Nester; Richard J H Smith Journal: Front Immunol Date: 2022-05-10 Impact factor: 8.786
Authors: Adrian M Shields; Alistair T Pagnamenta; Andrew J Pollard; Jenny C Taylor; Holger Allroggen; Smita Y Patel Journal: Front Immunol Date: 2019-06-07 Impact factor: 7.561
Authors: Abolghasem Tohidpour; Andrey V Morgun; Elizaveta B Boitsova; Natalia A Malinovskaya; Galina P Martynova; Elena D Khilazheva; Natalia V Kopylevich; Galina E Gertsog; Alla B Salmina Journal: Front Cell Infect Microbiol Date: 2017-06-20 Impact factor: 5.293
Authors: Sarah de Jong; Anita de Breuk; Bjorn Bakker; Suresh Katti; Carel B Hoyng; Sara C Nilsson; Anna M Blom; Lambert P van den Heuvel; Anneke I den Hollander; Elena B Volokhina Journal: Front Immunol Date: 2022-01-05 Impact factor: 7.561